Background: Despite the progression of dialysis techniques, the mortality of hemodialysis (HD) patients is still high in China. Here, a retrospective study was performed to investigate the neglected risk factors of all-cause mortality during maintenance HD (MHD). Methods: We investigated 117 MHD patients who died between 2011 and 2016 in the Second Xiangya Hospital of Central South University HD center. In order to analyze the risk factors of 48 months all-cause death, the methods of Kaplan-Meier and Cox regression were used. Results: Multivariate analyses of adjusted age and gender showed that MHD patients with estimated glomerular filtration rate < 7 or > 10 mL/min/1.73 m 2 and anemia (hemoglobin < 100 g/L) at the initiation of dialysis are independently associated with the higher death risk. Using central venous catheter vascular access, cerebrovascular comorbidities, diabetes, low-flux dialyzer, and dialysis frequency ≤2 times weekly were also the independent risk factors of death within 48 months. Conclusions: This study indicated that the status of HD initiation is a risk factor of long-term survival in MHD patients, which were usually ignored for lacking of nephrology care prior and could potentially be identified and modified to improve the survival prognosis. Video Journal Club "Cappuccino with Claudio Ronco" at https:// www.karger.com/Journal/ArticleNews/223997?sponsor=52
that in 2017, the number of patients receiving dialysis therapy was at least 596,365, and >85% was under hemodialysis (HD). The incidence was 80,000 per year from 2010 to 2017. The annual mortality rate of maintenance HD (MHD) in Beijing ranged from 7.4 to 9.0% in 2009 [2] , and it showed a declining trend and reached 6.4% in 2013 [3] .
Increased attention to potentially modifiable factors, which are associated with an increased risk of death, has been spawned for the very high mortality of HD patients compared to health people. Strong associated predictors of outcome are age, race, anemia, mineral-bone disease, vascular access type, dose of dialysis, inflammation, nutrition, psychosis state, nonrenal comorbidity, and so on [4, 5] . Intensive emphasis on these risk factors has resulted in a significant improvement in patient survival, with the mortality among HD patients falling 2-3% per year since 2001 [6] . However, the 4-year mortality in HD patients is still unacceptably high, which indicates that other factors may be neglected. Among these factors, some of them may be far away from spotlight but may play an indispensable role in affecting the mortality of HD patients. We performed a retrospective study to investigate the risk factors of all-cause mortality which might be ignored in HD patients.
Methods

Patient Selection
In this retrospective study, we included adult patients (≥18 years old) on MHD who died between January 1, 2012, and December 31, 2016 (n = 121) at the HD center of Second Xiangya Hospital of Central South University. Patients on MHD are defined as receiving HD therapy for >3 months. Patients, who received renal transplantation, underwent switches from peritoneal dialysis to HD, or received peritoneal dialysis and HD treatment meanwhile during the renal replacement treatment period were excluded.
The decision of study time span depended on the median survival time and the average survival time of the cohort. The study period and data collected were 48 months from starting of dialysis. The patients who survived < 48 months on HD were identified as dead, and those who survived ≥48 months on HD were identified as survived. We calculated the sample size according to the formula,
1.96 u a = δ = 0.1, α = 0.05, π = 0.6, n = 92. The sample size of our study is 117. We collected date from 117 HD patients and stratified these patients by survival time on HD (< 48 and ≥48 months) [7] .
Data Sources
Data were obtained from CNRDS [available at: http://www. cnrds.net/www/html/index.html] (in Chinese) and in-patients clinic data system of the Second Xiangya Hospital of Central South University. CNRDS is a register system for dialysis patients in China.
The gathered data encompassed the baseline demographics (age, gender, and the date of HD initiation), primary disease (diabetic nephropathy or nondiabetic nephropathy), comorbidities (presence of hypertension, coronary vascular disease, peripheral vascular disease, cerebrovascular disease, chronic respiratory disease, heart failure, malignancy), laboratory tests before HD initiation, including body mass index and estimated glomerular filtration rate (eGFR) calculated by using the modification of diet in renal disease. Serum albumin, hemoglobin (Hb), and whether the dialysis initiated unplanned/planned were recorded. Laboratory tests during maintenance dialysis period, including the average values of Hb, serum albumin, serum phosphorus, intact parathyroid hormone, ferroprotein, and serum lipid, were also recorded. The dialysis treatment information including dialysis vascular access, dialyzer flux, dialysis frequency, and medicine therapy (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and β-receptor blocker) was also documented. The death information was obtained from the CNRDS, including date and cause of death.
Statistical Analysis
All statistical operations were performed using the Statistical Package for Social Sciences for windows 19 
Results
Characteristics of Subgroup Patients
The study included 117 patients (37 female and 80 male), the average survival time of maintenance dialysis was 51.68 ± 35.15 months, and average age of initiation dialysis was 65.77 years. All the patients were divided into 2 groups depending on the survival time (< 48 and ≥48 months). The number of patients who survived longer than 48 months was 59, and the average survival time of maintenance dialysis was 78.98 ± 27.56 months. The number of those who survived shorter than 48 months was 58, and the average survival time of maintenance dialysis was 23.9 ± 13.59 months. The shorter survival time patients (< 48 months) tended to be older (≥70 years) than the longer survival time (≥48 months) patients at the initiation of HD. There were no significant differ-DOI: 10.1159/000497269 ences between these 2 groups with regard to gender, primary renal disease, and the cause of death. The most common primary renal diseases were diabetic nephropathy and hypertensive nephropathy, followed by primary glomerulonephritis, polycystic kidney disease, and others. Among those patients, the most common cause of death is cardio-cerebrovascular disease. Infection is also a very common cause of death in MHD patient (Table 1) .
Factors Associated with Survival in MHD Patients
The Kaplan-Meier analysis was used to estimate the risk factors associated with <48 months survival in maintenance dialysis patients. Our results indicated that the diabetic nephropathy and cerebrovascular disease were risk factors of death. Furthermore, the baseline characteristics at HD initiation also affected the survival length of HD patients, low serum albumin concentration (< 30 g/L), low Hb concentration (< 100 g/L), and baseline eGFR < 7 mL/min/1.73 m 2 or eGFR > 10 mL/min/1.73 m 2 at the initiation of HD were associated with short-time survival (< 48 months). More details are shown in Tables  2 and 3 .
Compared with the HD-related factors, the patients who used central venous catheter (CVC), low-flux diayzer, with HD frequency less or equal than 2 times weekly, Hb < 110 g/L, or been prescribed with β-receptor blocker had significantly shorter survival time (<48 months; Table 4).
Univariate Analysis of Death Risk
As shown in Table 5 and Figures 1 and 2 , univariate analysis showed that diabetes (HR 2.066, 95% CI 1.232-3.465), cerebrovascular disease (HR 2.544, 95% CI 1.511-4.283), serum albumin < 30 g/L (HR 2.446, 95% CI 1.448-4.132) or Hb < 100 g/L (HR 3.820, 95% CI 1.383-10.556), baseline eGFR < 7 mL/min/1.73 m 2 (HR 3.072, 95% CI 1.635-5.775) or eGFR > 10 mL/min/1.73 m 2 (HR 2.467, 95% CI 1.245-4.888) at the initiation of HD, using low-flux dialyzer (HR 2.094, 95% CI 1.217-3.63), using CVC vascular access (HR 11.932, CI 95% 5.038-28.263), HD frequency ≤2 times weekly (HR 2.120, 95% CI 1.246-3.606), Hb < 110 g/L (HR 2.917, 95% CI 1.595-5.334), and had not been prescribed with β-receptor blocker (HR 2.107, 95% CI 1.215-3.654) were closely associated with shorter survival time (< 48 months; Fig. 1 ). , Hb < 100 g/L at the initiation of HD, using low-flux dialyzer, CVC vascular access, HD frequency ≤2 times weekly and had not been prescribe with β-receptor blocker were significant independent risk factors of shorter survival time (< 48 months). After adjusting age and gender, the predialysis status (eGFR and Hb) seems one of the most important risk factors for HD patient survival. The results disclosed that baseline eGFR < 7 mL/min/ Fig. 2 ).
Patients' Survival
Kaplan-Meier survival curve is shown in Figure 3 . Among patients whose predialysis Hb ≥100 g/L or baseline eGFR 7-10 mL/min/1.73 m 2 , the survival time was significantly longer than those whose Hb < 100 g/L (42.1 vs. 80.0%, p = 0.015; a) or baseline eGFR < 7 or > 10 (29.0 vs. 41.7 vs. 69.4%, p = 0.001; b). Note that the statistically significant survival advantage of patients whose Hb ≥100 g/L and eGFR 7-10 mL/min/1.73 m 2 at initiation of HD (n = 11, 9.4%) and the cumulative survival rate of the patients whose eGFR < 7 or > 10, and Hb < 100 g/L at the initiation of HD were the lowest (n = 55, 48.2%; 32.7 vs. 60.8 vs. 90.9%, p < 0.001; c).
Discussion
In China, there are more and more oncoming ESRD patients forced to be treated with HD, which is considered as a modality of RRT for most ESRD patients. The present puzzle is that 4-year mortality in HD patients is still high despite technological progression and application of different HD techniques. In this study, we collected and analyzed the clinical information of MHD patients, the results showed that diabetic nephropathy, cerebrovascular disease co-morbidity, and HD factors (vascular access, HD frequency, and dialyzer) were independent factors influencing patient survival, which confirmed with other studies [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . What's more, the predialysis condition (eGFR and Hb) also affects long-term prognosis, which were previously thought to predict early mortality. This means that commence HD in an optimal timing is critical for improving long-term prognosis as well.
The ideal time to initiate HD is still controversial. The patients have substantially started HD earlier over the past 2 decades [20] . The patients who initiated HD at eGFR > 10 mL/min/1.73 m 2 has increased from 12.5% in 1996 to 40.5% in 2012 [21] . But recently, more and more trials and clinical observational studies had questioned this trend [22] [23] [24] [25] . According to the RCT trial IDEAL (Initiating Dialysis Early and Late) studied by Cooper et al. [26] , the results showed that no significant differences were noted between early (eGFR was 5.0-7.0 mL/min) and late (eGFR was 10.0-15.0 mL/min) starting HD therapy for cardiovascular death or nonfatal cardiovascular, all-cause mortality outcomes, quality of life, and so on. Wright et al. [27] also investigated the effect of the timing of starting HD on survival in HD patients in the United States. They discovered that earlier starting of HD was even associated with poor survival outcome. A meta-analysis [28] found that after increasing 1 mL/min/1.73 m 2 in the eGFR at the beginning of dialysis, all-cause mortality would elevated by 3-4% after adjustment for comorbid conditions.
Here, our results showed that the patients with the level of eGFR 7-10 mL/min/1.73 m 2 at HD initiation had the lowest mortality. A higher (> 10 mL/min/1.73 m 2 ) or lower (< 7 mL/min/1.73 m 2 ) eGFR was associated with higher mortality. The partial reason is that the patient initiated HD at higher eGFR usually reflects a poor general condition, especially the states of overhydration and even heart failure, and some specific characteristics including presence of other serious comorbidities [20, 29, 30] . Only the fittest patients could tolerate long enough and initiate HD later. Moreover, the eGFR or any index based on creatinine (or urea) is hardly accurate to predict the real renal function [31] . Therefore, it is hard to say that starting HD with higher eGFR implies a good condition at predialysis phase. Furthermore, our results concluded that the patients starting HD with higher eGFR (> 10 mL/min/1.73 m 2 ) had better outcome than the lower eGFR (< 7 mL/ min/1.73 m 2 ) patients. This may be because most of the patients who started with low eGFR (< 7 mL/min/1.73 m 2 ) had not received nephrologist reference or did not accept HD treatment until they obtained more severe symptoms or comorbidities which were associated with poor prognosis.
Lately, NKFKDOQI HD Adequacy Work Group has recommended that the decision to initiate maintenance dialysis therapy should be based primarily on the presence of symptomatic uremia, protein-energy wasting, metabolic abnormalities, and volume overload rather than on a specific level of kidney function [32] . This recommendation is slightly different from the 2006 guideline, which recommended a specific eGFR cutoff of 15 mL/min/1.73 m 2 for those who need HD therapy, but the new guideline did not provide an eGFR threshold for HD therapy initiation.
Anemia is highly prevalent in CKD patients, reported in up to 50% of predialysis CKD patients, and most of them haven't received rHuEPO treatment [33] . The results of this study indicated that 83.5% patients started HD with Hb < 100 g/L, and most of them were not treated with any drug to correct anemia. Furthermore, the lower Hb (< 100 g/L) in initiation of HD is an independent risk factor affecting long-term prognosis.
Recently, several studies found that ESRD patients with low Hb in initiation of HD suffered higher early mortality [34] . In DKD patients, the lower Hb (< 100 g/L) at referral to renal services before HD initiation also could predict death [35] . One of the important reasons is that the lower Hb is a risk factor of cardiovascular disease [36] . A study from Japan showed that lower Hb level is associated with growing cardiothoracic ratio enlargement in ESRD patients, and maintaining Hb level above 90 g/L could help protect from cardiac remodeling during the predialysis phase [37] .
Our results also showed that 48.2% patients who initiated HD with both low Hb (< 100 g/L) and lower or higher eGFR (< 7 or > 10 mL/min/1.73 m 2 ) had the lowest survival rate. A large part of these patients, due to late referral, have not started renal replacement treatment until electrolyte disturbances, malnutrition, volume overload, heart failure, or other complications are accompanied. They need urgent HD treatment, and a temporary catheter can increases the risk of catheter-related infections, leading to sepsis and even death. But the severe predialysis condition could be potentially modifiable. One of the most important strategies is early nephrologist care that can help patient manage their blood pressure, anemia, timely set up the vascular access and initiation HD treatment, and so on.
CKD patients who have not received adequate nephrology care prior to dialysis simply turn to a potentially sicker population of patients. Longer nephrology care prior to dialysis was associated with better first-year survival, higher albumin and Hb [39] . And other studies also showed that the late nephrologist referral is an independent risk factor for poor survival outcome on dialysis [40, 41] . The guidelines suggest that CKD patients should be assigned to the nephrologist for >1 year and be set up ad- equate vascular access up to 6 months before predicting dialysis.
For the anemia management, rHuEPO is one of the most effective prescriptions. A meta-analysis showed that rHuEPO treatment in predialysis patients corrected anemia, which could avoid blood transfusions requirement and improve life quality and exercise capacity [38] . A study indicated that patients who received multidisciplinary clinic care had higher level of Hb (102 vs. 90 g/L) at dialysis starting and significantly better survival rate than standard nephrologist care patients [42] . Early nephrologist care prior to HD on uremic patients with symptoms, especially for active management of anemia, close monitoring of renal function changes, timely access to HD treatment on prognosis of patients will have a positive impact on long-term prognosis.
Limitations of this Study
In this study, we obtained some useful results, but the number of limitations still should be considered to the conclusions drawn. This is a single-center retrospective study. Cohort population is death MHD patients, and the initiation HD period was different, which might affect the prognosis. As the dataset in this study is relatively limited, the comprehensive analysis of more factors was not feasible, including blood pressure, indicator of inflammation status, HD ultrafiltration volume, and so on. Those are also affecting the prognosis of the MHD patients. Therefore, a large multicenter prospective study should be done to identify more potential independent risk factors.
Conclusion
In this study, we demonstrated that except for elderly age, diabetic nephropathy, cerebrovascular disease comorbidities, HD frequency ≤2 times weekly, CVC vascular access, and low-flux dialyzer lead to the higher death risk of <48 months survive in MHD patients. What's more, the low concentration of Hb and too high or too low eGFR at the initiation of HD indicated the poor survival prognosis as well. So those potentially modifiable factors in predialysis and dialysis stage provide a valuable intervention opportunity for improving the survival prognosis.
